Sun Pharma temporarily halts shipments from manufacturing plant after FDA letter
Sun Pharma is pausing production at one of its plants in India after facing scrutiny by US regulators over necessary corrective work.
In a letter to the National Stock Exchange of India dated Sunday, Sun Pharma said it had been handed a letter from the FDA titled, “Consent Decree Correspondence/Non-Compliance Letter.” US regulators conveyed to Sun Pharma that it needs to take corrective actions at the manufacturing facility in the city of Mohali, India, in the Punjab region, before Sun can ship any products to the US.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.